These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 20459770)

  • 21. [Detection of EGFR and K-ras mutations in non-small cell lung cancer using cytological specimens].
    Lu SS; Xu X; Guo HQ; Cao J; Pan QJ; Wang MR
    Zhonghua Zhong Liu Za Zhi; 2013 Aug; 35(8):585-9. PubMed ID: 24314215
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab.
    Scartozzi M; Giampieri R; Maccaroni E; Mandolesi A; Giustini L; Silva R; Zaniboni A; Biscotti T; Biagetti S; Galizia E; Loupakis F; Falcone A; Bearzi I; Cascinu S
    Ann Oncol; 2012 Jul; 23(7):1706-12. PubMed ID: 22112971
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human papillomavirus and gene mutations in head and neck squamous carcinomas.
    Friedland P; Thomas A; Naran A; Amanuel B; Grieu-Iacopetta F; Carrello A; Harnett G; Meyer C; Phillips M
    ANZ J Surg; 2012 May; 82(5):362-6. PubMed ID: 22507644
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of Epidermal Growth Factor Receptor (EGFR) Gene Mutation in Formalin Fixed Paraffin Embedded Tissue by Polymerase Chain Reaction-Single Strand Conformational Polymorphism (PCR-SSCP) in Non-Small Cell Lung Cancer in the Northeastern Region of Thailand.
    Saiyaros K; Kritpetcharat P; Pairojkul C; Sithithaworn J
    Asian Pac J Cancer Prev; 2019 May; 20(5):1339-1343. PubMed ID: 31127887
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cross-validation study for epidermal growth factor receptor and KRAS mutation detection in 74 blinded non-small cell lung carcinoma samples: a total of 5550 exons sequenced by 15 molecular French laboratories (evaluation of the EGFR mutation status for the administration of EGFR-TKIs in non-small cell lung carcinoma [ERMETIC] project--part 1).
    Beau-Faller M; Degeorges A; Rolland E; Mounawar M; Antoine M; Poulot V; Mauguen A; Barbu V; Coulet F; Prétet JL; Bièche I; Blons H; Boyer JC; Buisine MP; de Fraipont F; Lizard S; Olschwang S; Saulnier P; Prunier-Mirebeau D; Richard N; Danel C; Brambilla E; Chouaid C; Zalcman G; Hainaut P; Michiels S; Cadranel J
    J Thorac Oncol; 2011 Jun; 6(6):1006-15. PubMed ID: 21532509
    [TBL] [Abstract][Full Text] [Related]  

  • 26. No evidence of oncogenic KRAS mutations in squamous cell carcinomas of the anogenital tract and head and neck region independent of human papillomavirus and p16(INK4a) status.
    Prigge ES; Urban K; Stiegler S; Müller M; Kloor M; Mai S; Ottstadt M; Lohr F; Wenz F; Wagner S; Wittekindt C; Klussmann JP; Hampl M; von Knebel Doeberitz M; Reuschenbach M
    Hum Pathol; 2014 Nov; 45(11):2347-54. PubMed ID: 25257576
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of epidermal growth factor receptor and K-ras mutation status in cytological stained smears of non-small cell lung cancer patients: correlation with clinical outcomes.
    Lozano MD; Zulueta JJ; Echeveste JI; Gúrpide A; Seijo LM; Martín-Algarra S; Del Barrio A; Pio R; Idoate MA; Labiano T; Perez-Gracia JL
    Oncologist; 2011; 16(6):877-85. PubMed ID: 21572125
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epidermal growth factor receptor (EGFR) expression and mutations in the EGFR signaling pathway in correlation with anti-EGFR therapy in head and neck squamous cell carcinomas.
    Smilek P; Neuwirthova J; Jarkovsky J; Dusek L; Rottenberg J; Kostrica R; Srovnal J; Hajduch M; Drabek J; Klozar J
    Neoplasma; 2012; 59(5):508-15. PubMed ID: 22668015
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The value of biomarkers in patients with sarcomatoid carcinoma of the lung: molecular analysis of 33 cases.
    Jiang X; Liu Y; Chen C; Zhan Z; Yan Q; Guo Y; Wang Q; Li K
    Clin Lung Cancer; 2012 Jul; 13(4):288-96. PubMed ID: 22169481
    [TBL] [Abstract][Full Text] [Related]  

  • 30. KRAS, EGFR, PDGFR-α, KIT and COX-2 status in carcinoma showing thymus-like elements (CASTLE).
    Veits L; Schupfner R; Hufnagel P; Penzel R; Freitag J; Ströbel P; Kern MA; Schröder S; Neuhold N; Schmid KW; Schirmacher P; Hartmann A; Rieker RJ
    Diagn Pathol; 2014 Jun; 9():116. PubMed ID: 24934485
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical significance of KRAS gene mutation and epidermal growth factor receptor expression in Japanese patients with squamous cell carcinoma of the larynx, oropharynx and hypopharynx.
    Fujii S; Uryu H; Akashi K; Suzuki K; Yamazaki M; Tahara M; Hayashi R; Ochiai A
    Int J Clin Oncol; 2013 Jun; 18(3):454-63. PubMed ID: 22441881
    [TBL] [Abstract][Full Text] [Related]  

  • 32. EGFR and K-ras mutation analysis in non-small cell lung cancer: comparison of paraffin embedded versus frozen specimens.
    Gallegos Ruiz MI; Floor K; Rijmen F; Grünberg K; Rodriguez JA; Giaccone G
    Cell Oncol; 2007; 29(3):257-64. PubMed ID: 17452778
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer.
    Sánchez-Muñoz A; Gallego E; de Luque V; Pérez-Rivas LG; Vicioso L; Ribelles N; Lozano J; Alba E
    BMC Cancer; 2010 Apr; 10():136. PubMed ID: 20385028
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer.
    Grob TJ; Heilenkötter U; Geist S; Paluchowski P; Wilke C; Jaenicke F; Quaas A; Wilczak W; Choschzick M; Sauter G; Lebeau A
    Breast Cancer Res Treat; 2012 Jul; 134(2):561-7. PubMed ID: 22610646
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EGFR and p53 status of pulmonary pleomorphic carcinoma: implications for EGFR tyrosine kinase inhibitors therapy of an aggressive lung malignancy.
    Chang YL; Wu CT; Shih JY; Lee YC
    Ann Surg Oncol; 2011 Oct; 18(10):2952-60. PubMed ID: 21409490
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EGFR status and KRAS/BRAF mutations in intestinal-type sinonasal adenocarcinomas.
    García-Inclán C; López F; Pérez-Escuredo J; Cuesta-Albalad MP; Vivanco B; Centeno I; Balbín M; Suárez C; Llorente JL; Hermsen MA
    Cell Oncol (Dordr); 2012 Dec; 35(6):443-50. PubMed ID: 23055340
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular characterization of EGFR and EGFR-downstream pathways in triple negative breast carcinomas with basal like features.
    Martin V; Botta F; Zanellato E; Molinari F; Crippa S; Mazzucchelli L; Frattini M
    Histol Histopathol; 2012 Jun; 27(6):785-92. PubMed ID: 22473698
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comprehensive molecular analyses of lung adenocarcinoma with regard to the epidermal growth factor receptor, K-ras, MET, and hepatocyte growth factor status.
    Onitsuka T; Uramoto H; Ono K; Takenoyama M; Hanagiri T; Oyama T; Izumi H; Kohno K; Yasumoto K
    J Thorac Oncol; 2010 May; 5(5):591-6. PubMed ID: 20150826
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epidermal growth factor receptor (EGFR)-RAS signaling pathway in penile squamous cell carcinoma.
    Gou HF; Li X; Qiu M; Cheng K; Li LH; Dong H; Chen Y; Tang Y; Gao F; Zhao F; Men HT; Ge J; Su JM; Xu F; Bi F; Gao JJ; Liu JY
    PLoS One; 2013; 8(4):e62175. PubMed ID: 23637996
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study.
    Schneider CP; Heigener D; Schott-von-Römer K; Gütz S; Laack E; Digel W; Guschall WR; Franke A; Bodenstein H; Schmidtgen C; Reck M
    J Thorac Oncol; 2008 Dec; 3(12):1446-53. PubMed ID: 19057271
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.